Hematologic Malignancies Clinical Trials in Houston, Texas
10 recruitingHouston, Texas
Showing 1–10 of 10 trials
Recruiting
Phase 1Phase 2
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Hematologic Malignancies
Sellas Life Sciences Group160 enrolled25 locationsNCT04588922
Recruiting
Phase 3
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
Solid TumorsHematologic Malignancies
Merck Sharp & Dohme LLC3,500 enrolled779 locationsNCT03486873
Recruiting
Phase 2
Optimized Cord Blood Transplantation for the Treatment of Patients With High-risk Hematologic Malignancies Who Have Relapsed After First Allogeneic Stem Cell Transplantation
Hematologic Malignancies
M.D. Anderson Cancer Center35 enrolled1 locationNCT06807606
Recruiting
Phase 2
PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV)
Hematologic MalignanciesHematopoietic Stem Cell Transplant (HSCT)
Pulmotect, Inc.100 enrolled11 locationsNCT06665100
Recruiting
Phase 1
A Phase 1 Study of IM-1021 in Participants With Advanced Cancer
Hematologic MalignanciesSolid Malignancies
Immunome, Inc.117 enrolled13 locationsNCT06823167
Recruiting
Phase 1
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
Solid TumorsHematologic Malignancies
Incyte Corporation280 enrolled22 locationsNCT07195916
Recruiting
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Hematologic MalignanciesInherited Disorders of MetabolismInherited Abnormalities of Platelets+2 more
Center for International Blood and Marrow Transplant Research99,999 enrolled142 locationsNCT01351545
Recruiting
Phase 1
How [14C]-DSP-5336 is Absorbed, Broken Down, and Removed From the Body After a Single Oral Dose in Patients With Advanced Blood Cancers
Advanced Hematologic Malignancies
Sumitomo Pharma America, Inc.8 enrolled2 locationsNCT07444268
Recruiting
Phase 1
Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
Myelodysplastic SyndromesRelapsed or Refractory Acute Myeloid Leukemia (AML)Untreated AML+1 more
Institut de Recherches Internationales Servier291 enrolled30 locationsNCT02074839
Recruiting
Early Phase 1
APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic Malignancies
Hematologic Malignancies
Ascentage Pharma Group Inc.90 enrolled5 locationsNCT03537482